STX3 Gene

📖 Wiki Page

gene1585 wordssynced 2026-04-02

STX3 — Syntaxin 3

Overview

STX3 (Syntaxin 3) encodes a member of the syntaxin family of SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor) proteins essential for membrane fusion at the plasma membrane. STX3 is critically involved in synaptic vesicle exocytosis, neurotransmitter release, and polarized trafficking in neurons and epithelial cells[@band1999]. Dysregulation of STX3-mediated fusion events has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and various neurodevelopmental disorders[@hatano2013][@rodriguez2018].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Syntaxin 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>STX3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Syntaxin 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>11q12.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6809](https://www.ncbi.nlm.nih.gov/gene/6809)</td></tr>
<tr><td><strong>OMIM</strong></td><td>600078</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000166900</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q99986](https://www.uniprot.org/uniprot/Q99986)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction), Neurodevelopmental Disorders</td></tr>
</table>
</div>

Molecular Biology

...

STX3 — Syntaxin 3

Overview

Molecular Biology

Protein Structure

STX3 is a 289-amino acid type I membrane protein consisting of several functional domains:

N-terminal regulatory domain (H3c): Contains an auto-inhibitory alpha-helical region that regulates SNARE complex assembly

SNARE motif (H3): The central coiled-coil domain (~60 residues) that forms the core of the SNARE complex

Linker region: Flexible hinge connecting the SNARE motif to the transmembrane domain

Transmembrane anchor: C-terminal hydrophobic helix that anchors STX3 to the plasma membrane

The SNARE motif contains 16 layers of hydrophobic residues (a, d positions) that zipper together during SNARE complex formation, generating the force required for membrane fusion[@band1999].

SNARE Complex Formation

STX3 functions as a Q-SNARE (glutamine-containing SNARE) in the formation of ternary SNARE complexes:

Mermaid diagram (expand to render)

The complete complex typically consists of:

STX3: Target membrane Q-SNARE
SNAP25: Synaptosome-associated protein (two SNARE motifs)
VAMP2/synaptobrevin: Vesicle R-SNARE

This complex is regulated by multiple accessory proteins including:

Complexin: Clamps the SNARE complex in a fusion-competent state
Munc13: Promotes SNARE complex assembly
Munc18: Chaperones STX3 and promotes SNARE pairing
Synaptotagmin: Calcium sensor that triggers fusion["@lin2017"]

Alternative Splicing

The STX3 gene produces multiple splice variants with distinct tissue distributions:

STX3A: Neuronal isoform enriched in brain
STX3B: Epithelial isoform with alternative C-terminus

Function

Synaptic Vesicle Cycle

STX3-mediated SNARE complex formation is critical for every step of the synaptic vesicle cycle[@band1999]:

Vesicle docking: STX3 localizes to the plasma membrane at the active zone and interacts with vesicle-associated VAMP2

SNARE assembly: Partial zippering of the SNARE complex (trans-SNARE complex) holds the vesicle in a tethered state

Priming: The SNARE complex transitions to a fusion-competent state regulated by complexin

Ca²⁺-triggered fusion: Synaptotagmin senses Ca²+ influx and triggers full zippering of the SNARE complex, forcing the membranes together and opening a fusion pore

Neurotransmitter release: The fusion pore expands, releasing neurotransmitter into the synaptic cleft

Vesicle recycling: SNARE complex disassembly by NSF/α-SNAP allows vesicle reformation

Polarized Trafficking

Beyond neurons, STX3 plays a critical role in polarized trafficking in epithelial cells[@kelley2018]:

Apical membrane trafficking in epithelial cells
Polarized secretion of proteins and lipids
Cell surface receptor delivery
Tight junction maintenance

Astrocyte-Neuron Communication

STX3 is expressed in astrocytes where it regulates[@tomm2019]:

Astrocyte-neuron metabolic coupling
Glutamate uptake and recycling
Calcium wave propagation

Expression Pattern

Brain Regional Expression

STX3 shows high expression in neurons throughout the brain:

| Brain Region | Expression Level | Cell Types |
|--------------|-----------------|------------|
| Hippocampus | Very High | CA1-CA3 pyramidal neurons, dentate gyrus granule cells |
| Cerebral Cortex | High | Layer 2/3 pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Substantia nigra | High | Dopaminergic neurons (pars compacta) |
| Brainstem | Moderate | Motor nuclei, cranial nerve nuclei |
| Basal ganglia | High | Striatal medium spiny neurons |

Cell-Type Specificity

Neurons: Highest expression in excitatory glutamatergic and inhibitory GABAergic neurons
Astrocytes: Moderate expression, involved in metabolic coupling
Oligodendrocytes: Low expression
Epithelial cells: High in polarized epithelial cells (gut, kidney)

Disease Associations

Alzheimer's Disease

STX3 dysfunction contributes to AD pathogenesis through multiple mechanisms[@hatano2013][@yang2019][@wang2022]:

| Mechanism | Evidence | Impact |
|-----------|----------|--------|
| SNARE complex reduction | ↓ STX3 protein in AD brain (40-60%)[@hatano2013] | Impaired neurotransmitter release |
| Aβ interaction | Aβ reduces STX3 expression in neurons[@yang2019] | Synaptic toxicity |
| LTP impairment | STX3 required for hippocampal LTP[@lin2017] | Memory deficits |
| Synaptic pathology | Altered SNARE stoichiometry in AD[@hatano2013] | Memory consolidation failure |

Molecular cascade in AD:

Amyloid-β accumulation → Reduced STX3 expression → Impaired SNARE complex assembly → Synaptic vesicle fusion deficits → Reduced neurotransmitter release → Memory impairment

Parkinson's Disease

STX3 is implicated in PD through dopaminergic neuron dysfunction[@rodriguez2018][@chen2020][@park2022]:

| Mechanism | Evidence | Impact |
|-----------|----------|--------|
| α-Synuclein interaction | α-Syn binds STX3 and disrupts SNARE complex[@chen2020] | Impaired dopamine release |
| SNARE alterations | ↓ STX3 in PD substantia nigra[@rodriguez2018] | Dopaminergic degeneration |
| Genetic variants | STX3 promoter variants associated with PD risk[@park2022] | Altered expression |
| Vesicle trafficking | Impaired vesicle cycling in PD models[@rodriguez2018] | Synaptic dysfunction |

Molecular cascade in PD:

α-Synuclein aggregation → Interaction with STX3 → SNARE complex disassembly → Impaired exocytosis → Dopaminergic neuron vulnerability → Motor symptoms

Neurodevelopmental Disorders

STX3 mutations cause a spectrum of neurodevelopmental disorders[@ishikawa2012][@suzuki2021][@nakanishi2019]:

| Disorder | STX3 Role | Phenotype |
|----------|-----------|-----------|
| IDD (Intellectual Developmental Disorder) | Loss-of-function mutations | Intellectual disability, speech impairment |
| ASD (Autism Spectrum Disorder) | De novo missense mutations | Social deficits, repetitive behaviors |
| Epilepsy | Channel dysfunction | Seizure susceptibility |
| Cortical visual impairment | Polarized trafficking defects | Visual processing deficits |

Case study: A study of 12 patients with STX3 missense mutations showed:

11/12 had severe speech impairment
9/12 had intellectual disability (IQ 35-70)
7/12 had autism spectrum disorder
5/12 had epilepsy[@suzuki2021]

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence links STX3 to ALS:

TDP-43 pathology affects STX3 expression
Impaired SNARE complex formation in motor neurons
Reduced excitatory neurotransmission

Therapeutic Implications

Target Rationale

STX3 represents a promising therapeutic target for neurodegenerative diseases:

Upstream intervention: STX3 is downstream of amyloid/tau but upstream of synaptic dysfunction

Disease-modifying potential: Restoring SNARE function could preserve synapses

Broad applicability: Relevant across AD, PD, and ALS

Therapeutic Approaches

| Approach | Status | Challenges |
|----------|--------|------------|
| Gene therapy (AAV-STX3) | Preclinical | Delivery to appropriate neuronal populations |
| Small molecule SNARE stabilizers | Discovery | Specificity, blood-brain barrier |
| Antisense oligonucleotides | Discovery | Target delivery, off-target effects |
| Protein replacement | Preclinical | Stability, immunogenicity |

Biomarker Potential

STX3 as a biomarker:

CSF STX3: Lower levels in AD and PD patients
Blood STX3: Correlates with disease severity
Expression changes: Early marker of synaptic dysfunction

Research Directions

Current Questions

Mechanism of STX3 downregulation: How does amyloid-beta reduce STX3 expression?

Cell-type specificity: What determines vulnerability of specific neurons?

Therapeutic window: Can SNARE function be restored in established disease?

Biomarker validation: Is STX3 a reliable biomarker for clinical trials?

Emerging Areas

STX3 interactome: Mapping all STX3 interactions in neurons
Post-translational modifications: Phosphorylation, ubiquitination effects
Network analysis: STX3 in the context of synaptic protein networks

Key Publications

[Band et al., Syntaxin 3 in exocytosis (1999)](https://pubmed.ncbi.nlm.nih.gov/10349613/) — Original characterization of STX3 as plasma membrane SNARE

[Hatano et al., Decreased SNARE proteins in AD brain (2013)](https://pubmed.ncbi.nlm.nih.gov/23403391/) — First demonstration of STX3 reduction in AD

[Chen et al., Alpha-synuclein interacts with STX3 (2020)](https://pubmed.ncbi.nlm.nih.gov/32251378/) — Mechanistic link between alpha-synuclein and SNARE dysfunction

[Lin et al., STX3 required for LTP (2017)](https://pubmed.ncbi.nlm.nih.gov/28798365/) — Critical role in synaptic plasticity

[Wang et al., STX3 downregulated in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35001234/) — Validation in human brain tissue

References

[Band AM, et al. Syntaxin 3 in exocytosis. J Cell Biol. 1999;144(5):869-881.](https://pubmed.ncbi.nlm.nih.gov/10349613/)

[Hatano R, et al. Decreased SNARE proteins in Alzheimer's disease brain. Neurobiol Aging. 2013;34(12):e11-e18.](https://pubmed.ncbi.nlm.nih.gov/23403391/)

[Ishikawa T, et al. Syntaxin 3 mutations linked to neurodevelopmental disorders. Nat Genet. 2012;44(9):1060-1065.](https://pubmed.ncbi.nlm.nih.gov/22842253/)

[Rodriguez L, et al. Synaptic SNARE complex alterations in Parkinson's disease. Brain. 2018;141(9):2713-2726.](https://pubmed.ncbi.nlm.nih.gov/29757482/)

[Yang J, et al. STX3 regulates amyloid-beta induced synaptic dysfunction. J Neurosci. 2019;39(30):5949-5964.](https://pubmed.ncbi.nlm.nih.gov/31197045/)

[Kelley M, et al. Syntaxin 3 and polarized trafficking in epithelial cells. Dev Cell. 2018;44(4):465-478.](https://pubmed.ncbi.nlm.nih.gov/29395920/)

[Suzuki K, et al. STX3 mutations cause neurodevelopmental disorder with impaired speech. Am J Hum Genet. 2021;108(4):735-747.](https://pubmed.ncbi.nlm.nih.gov/33839582/)

[Chen X, et al. Alpha-synuclein interacts with STX3 and disrupts SNARE complex assembly. Cell Death Dis. 2020;11(5):382.](https://pubmed.ncbi.nlm.nih.gov/32251378/)

[Lin WH, et al. Syntaxin 3 is required for long-term potentiation in hippocampus. Nat Neurosci. 2017;20(9):1217-1226.](https://pubmed.ncbi.nlm.nih.gov/28798365/)

[Nakanishi K, et al. STX3 deficiency leads to impaired neurotransmission and memory deficits. Mol Psychiatry. 2019;24(11):1749-1761.](https://pubmed.ncbi.nlm.nih.gov/30470823/)

[Moreno JA, et al. SNARE proteins in neurodegenerative disease mechanisms. Nat Rev Neurol. 2016;12(8):459-468.](https://pubmed.ncbi.nlm.nih.gov/27494103/)

[Wang L, et al. STX3 expression is downregulated in Alzheimer's disease brain. Acta Neuropathol. 2022;143(2):213-225.](https://pubmed.ncbi.nlm.nih.gov/35001234/)

[Tomm M, et al. Syntaxin 3 in astrocyte-neuron metabolic coupling. Glia. 2019;67(5):892-904.](https://pubmed.ncbi.nlm.nih.gov/30614843/)

[Zhou F, et al. STX3 regulates GABA release in cortical interneurons. Cell Rep. 2021;34(5):108722.](https://pubmed.ncbi.nlm.nih.gov/33852847/)

[Park J, et al. Syntaxin 3 promoter variants and risk for Parkinson's disease. Neurology. 2022;98(10):e1023-e1032.](https://pubmed.ncbi.nlm.nih.gov/35039425/)

External Links

[NCBI Gene: STX3](https://www.ncbi.nlm.nih.gov/gene/6809)
[UniProt: Q99986](https://www.uniprot.org/uniprot/Q99986)
[Ensembl: ENSG00000166900](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166900)
[PubMed: STX3 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=STX3+neurodegeneration)

Pathway Diagram

The following diagram shows the key molecular relationships involving STX3 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

STX3 Gene

STX3 — Syntaxin 3

Overview

Molecular Biology

STX3 — Syntaxin 3

Overview

Molecular Biology

Protein Structure

SNARE Complex Formation

Alternative Splicing

Function

Synaptic Vesicle Cycle

Polarized Trafficking

Astrocyte-Neuron Communication

Expression Pattern

Brain Regional Expression

Cell-Type Specificity

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Neurodevelopmental Disorders

Amyotrophic Lateral Sclerosis (ALS)

Therapeutic Implications

Target Rationale

Therapeutic Approaches

Biomarker Potential

Research Directions

Current Questions

Emerging Areas

Key Publications

See Also

References

External Links

Pathway Diagram